INTRODUCTION {#sec0005}
============

The Huntington's Disease Clinical Trials Corner is a regular section devoted to highlighting ongoing and recently completed clinical trials in Huntington's disease (HD). Clinical trials previously reviewed by the Huntington's Disease Clinical Trials Corner are listed in [Table 1](#jhd-7-jhd189003-t001){ref-type="table"}.

###### 

Clinical trials previously reviewed by the Huntington's Disease Clinical Trials Corner

  Registration ID     Trial name       Intervention               Edition
  ----------------- --------------- ------------------ ------------------------------
  NCT02519036         IONIS-HTTRx     IONIS-HTT~Rx~     September 2017 \[[@ref004]\]
  NCT02215616          LEGATO-HD        Laquinimod     
  NCT02197130          Amaryllis       PF-02545920     
  NCT02006472          Pride-HD        Pridopidine     
  NCT03225833        PRECISION-HD1      WVE-120101      February 2018 \[[@ref015]\]
  NCT03225846        PRECISION-HD2      WVE-120102     
  NCT01795859          FIRST-HD      Deutetrabenazine  
  NCT02481674           SIGNAL          VX15/2503               August 2018
  NCT00712426           CREST-E          Creatine      

In this edition, we highlight the SIGNAL trial (NCT02481674) \[[@ref001]\], and summarise the results of the recently published CREST-E trial (NCT00712426) \[[@ref002]\]. Finally we tabulate all currently registered and ongoing clinical trials in [Tables 2](#jhd-7-jhd189003-t002){ref-type="table"} to [4](#jhd-7-jhd189003-t002){ref-type="table"}. For further details on the methodology used, please refer to the September 2017 edition of Huntington's Disease Clinical Trials Corner \[[@ref004]\].

###### 

Ongoing pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD)

  Registration ID          Trial name          Intervention    Mechanism of                                    Population                                                               Comparison   Main outcome                                           Study design                                                                                                 Estimated   Sponsor                                                                                                          Location
  ------------------------ ------------------- --------------- ----------------------------------------------- ------------------------------------------------------------------------ ------------ ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ----------- ---------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  NCT03342053              IONIS-HTT~RX~ OLE   ISIS 443139     Allele-nonselective antisense oligonucleotide   HD                                                                       None         Safety and tolerability at 74 weeks                    Open label extension                                                                                         46          Ionis Pharmaceuticals Inc.                                                                                       Canada, Germany and UK (multi-centre)
  NCT03225833              PRECISION-HD1       WVE-120102      Allele-selective antisense oligonucleotide      HD                                                                       Placebo      Safety and tolerability at 1 and 120 days              Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial   48          Wave Life Sciences Ltd.                                                                                          Canada and Poland (multi-centre)
  NCT03225846              PRECISION-HD2       WVE-120102      Allele-selective antisense oligonucleotide      HD                                                                       Placebo      Safety and tolerability at 1 and 120 days              Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial   48          Wave Life Sciences Ltd.                                                                                          Canada and Poland (multi-centre)
  NCT02453061              TRIHEP 3            Triheptanoin    Anaplerotic therapy                             HD                                                                       Placebo      Pharmacodynamic efficacy at 6 months                   Randomized, double-blind, placebo-controlled, parallel trial                                                 100         Institut National de la Santé Et de la Recherche Médicale, Ultragenyx Pharmaceutical Inc                         France, Netherlands (multi centre)
  NCT02509793              --                  Tetrabenazine   VMAT2 inhibitor                                 HD with impulsivity                                                      None         Cognitive and behavioural effects at 8 weeks           Single group, open-label trial                                                                               20          University of Texas Health Science Center, and H. Lundbeck A/S                                                   USA (single centre)
  NCT02507284              STAIR               SRX246          Vasopressin 1a Receptor Antagonist              Early and moderate HD with irritability                                  Placebo      Feasibility at 12 weeks                                Randomized, double-blind, placebo-controlled, parallel trials                                                108         Azevan Pharmaceuticals, National Institute of Neurological Disorders and Stroke (NINDS), and NeuroNEXT Network   USA (multi centre)
  NCT02481674              SIGNAL              VX15/2503       Anti-semaphorin 4D monoclonal antibody          Late premanifest or early HD                                             Placebo      Safety and tolerability at 15 and 21 months            Randomized, double-blind, placebo-controlled, parallel trial                                                 240         Vaccinex Inc., Huntington Study Group                                                                            USA (multi centre)
  NCT02336633              REVHD               Resveratrol     Dietary supplement                              HD                                                                       Placebo      Neuroimaging biomarkers at 1 year                      Randomized, double-blind, placebo-controlled, parallel trial                                                 102         Assistance Publique - Hôpitaux de Paris                                                                          France (multi centre)
  NCT02215616              LEGATO-HD           Laquinimod      Immunomodulatory molecule                       HD                                                                       Placebo      Efficacy at 1, 3, 6, and 12 months                     Randomized, double-blind, placebo-controlled, parallel trial                                                 400         Teva Branded Pharmaceutical Products, R&D Inc.                                                                   Canada, Czech Republic, France, Germany, India, Israel, Italy, Netherlands, Portugal, Russia, Spain, UK, USA (multi centre)
  EUCTR2013-002545-10-SE   OSU6162Open1309     (--)-OSU616     Monoaminergic stabilizer                        HD, PD, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy   None         Safety at 3, 6 and 12 months                           Single group, open-label trial                                                                               240         A. Carlsson Research AB                                                                                          Sweden (multi centre)
  NCT00652457              MEM-HD              Memantine       NMDA receptor antagonist                        HD and memory or concentration difficulties                              Placebo      Efficacy at 3 and 6 months                             Randomized, double-blind, placebo-controlled, cross-over trial                                               60          University of California, San Diego, Forest Laboratories                                                         USA (multi centre)
  NCT00514774              UDCA-HD             Ursodiol        Bile acid                                       HD                                                                       Placebo      Safety, tolerability and pharmacokinetics at 35 days   Randomized, double-blind, placebo-controlled, parallel trial                                                 21          Oregon Health and Science University, Huntington Study Group, Huntington Society of Canada                       N/S
  ACTRN12616001611415      VCAS-HD             Varenicline     Nicotinic acid receptor partial agonist         HD                                                                       Placebo      Efficacy at 10 weeks                                   Randomized, double-blind, placebo-controlled, parallel trial                                                 40          University of Auckland                                                                                           New Zealand (single centre)

N/S, not specified; PD, Parkinson's disease; VMAT2, Vesicular Monoamine Transporter 2. New trials since the last Clinical Trials Corner are indicated by ^\*^.

###### 

Ongoing invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD)

  Registration ID    Trial name                   Intervention                             Mechanism of Action                                     Population                              Comparison                       Main outcome                                            Study design                           Esimated Enrolment                                                  Sponsor                                                                    Location
  ----------------- ------------ ---------------------------------------------- ----------------------------------------- ------------------------------------------------------------ ------------------- ----------------------------------------------- -------------------------------------------------------------- -------------------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------
  NCT03252535         ADORE-HD                     Cellavita                                Stem cell therapy                                          HD                                    Placebo                    Efficacy at 120 days                Randomized, double-blind, placebo-controlled, parallel trial           35                                                       Azidus Brasil                                                          Brazil (single centre)
  NCT03297177            --              Autologous stem/stromal cells           Autologous stem/stromal cell injection                       HD, AD, PD, CBD, MS                             None                        Safety at 5 years                                Single group, open-label trial                         300                     Healeon Medical Inc, Global Alliance for Regenerative Medicine, Regeneris Medical                   USA and Honduras (multi-centre)
  NCT02535884          HD-DBS                        GP DBS                              Deep brain stimulation                             Moderate HD with chorea                     Sham intervention               Efficacy at 12 months                Randomized, double-blind, sham-controlled, parallel trial             50           Heinrich-Heine University, KKS Netzwerk, Medtronic, The George Institute, EHDN, CHDI Foundation, Inc.   Austria, Germany, Switzerland (multi centre)
  NCT01834053          BMACHC          Bone Marrow Derived MNC transplant                Bone marrow transplant                                  HD with chorea                               None          Cognitive and behavioural effects at 6 months                  Single group, open-label trial                          50                                                 Chaitanya Hospital, Pune                                                     India (single centre)
  NCT02263430            --                          GP DBS                              Deep brain stimulation                                  HD with chorea                         Sham stimulation                Efficacy at 12 months               Randomized, double-blind, placebo-controlled, parallel trial           8                                   Beijing Pins Medical Co., Ltd, Beijing Tiantan Hospital                                     China (single centre)
  NCT02252380            --       Magnetic Resonance Guided Focused Ultrasound   Extracranial stereotactic radioablation   HD, ET, HT, PD, WD, dystonia, TD, or orofacial dyskinesias         None               Adverse events after the procedure                        Single group, open-label trial                          10                                                         InSightec                                                            Canada (single centre)

AD, Alzheimer's disease, CBD; Corticobasal Degeneration; DBS, deep brain stimulation; ET, Essential Tremor; GP, Globus pallidus; HT, Holmes Tremor; MNC, mononuclear cells; MS, Multiple Sclerosis; PD, Parkinson's disease; TD, Tardive dyskinesia; WD, Wilson's disease. New trials since the last Clinical Trials Corner are indicated by ^\*^.

###### 

Ongoing non-invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials Research Platform (ICTRP) for people with Huntington's disease (HD)

  Registration ID          Trial name                        Intervention                               Mechanism of Action                                       Population                                   Comparison                                                   Main outcome                                                                                          Study design                                              Esimated Enrolment                                         Sponsor                                                        Location
  ----------------------- ------------ -------------------------------------------------------- ----------------------------------- ---------------------------------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -------------------- -------------------------------------------------------------------------------------- ---------------------------------------
  CTRI/2018/01/011359\*        --            Repetitive transcranial magnetic stimulation        Transcranial magnetic stimulation                       Early to moderate HD and PD                        Sham stimulation                                             Efficacy at 5 days                                                               Randomized, single-blind, placebo-controlled, parallel trial                              40                                               Vinay Goyal                                                India (single centre)
  NCT03344601               PACE-HD     Supported structured aerobic exercise training program             Physiotherapy                                              HD                                    Activity as usual   Data completeness, recruitment, retention, asfety, adherence, fidelity and acceptability at 12 months                        Nested open-label,randomized controlled parallell trial                               120                               Cardiff University and CHDI Foundation, Inc                        Germany, Spain and USA (multi centre)
  NCT03306888                  --              Physical Activity Coaching Intervention                     Physiotherapy                                   Premanifest and early HD                               None                                         Change in physical activity at 4 months                                                                   Single group, open-label trial                                             14                                           Columbia University                                             USA (single centre)
  ACTRN12617001269325          --                     Swallowing skill training                     Speech and language therapy                                   HD and ALS                                      None                                   Swallowing function and quality of life at 2 weeks                                                              Single group, open-label trial                                             54                                         University of Canterbury                                      New Zealand (single centre)
  NCT02990676              CogTrainHD              Computerised Cognitive Training                      Cognitive training                                            HD                                     No intervention                                           Feasibility at 4 years                                                                        Open-label, controlled, parallel trial                                         50                                            Cardiff University                                             UK (single centre)
  NCT02464293                  --                Mindfulness-based Cognitive Therapy                     Cognitive therapy                    Premanifest and early HD with behavioural symptoms                  None                                   Behavioural effect at 2 weeks, 3 months and 1 year                                                              Single group, open-label trial                                             16            Lancaster University, Central Manchester University Hospitals NHS Foundation Trust             UK (single centre)
  NCT02216474                  --                                tDCS                            Transcranial magnetic stimulation                         HD or Tourette Syndrome                          Sham stimulation                                             Efficacy at 2 weeks                                                             Randomized, double-blind, placebo-controlled, cross-over trial                            100           Birmingham and Solihull Mental Health NHS Foundation Trust, University of Birmingham            UK (single centre)
  NCT02750982                  --                          Laughter Therapy                              Cognitive therapy           HD, AD, ALS, brain injury, MS, PD, post/stroke or spinal cord injury         None                                             Behavioural effects at 8 weeks                                                                        Single group, open-label trial                                             24                                      Brown, Theodore R., M.D., MPH                                        USA (single centre)
  NCT01602276                  --                                tDCS                            Transcranial magnetic stimulation                  Subcortical brain damage, including HD                  Sham stimulation                                             Efficacy at 1 month                                            Randomized, single-blind, placebo-controlled, cross-over trial, with parallel healthy control arm          150                                         Johns Hopkins University                                          USA (single centre)

AD, Alzheimer's disease; ALS, Amyotrophic Lateral Sclerosis; ET, Essential Tremor; HT, Holmes Tremor; MS, Multiple Sclerosis; PD, Parkinson's disease; TD, Tardive dyskinesia. New trials since the last Clinical Trials Corner are indicated by ^\*^.

If you would like to draw attention to specific trials, please feel free to email us at: <f.rodrigues@ucl.ac.uk> and <e.wild@ucl.ac.uk>.

ONGOING CLINICAL TRIALS {#sec0010}
=======================

A list of all ongoing clinical trials is given in [Tables 2](#jhd-7-jhd189003-t002){ref-type="table"}-- [4](#jhd-7-jhd189003-t004){ref-type="table"}.

SIGNAL (NCT02481674) {#sec0015}
--------------------

### Study title {#sec0020}

VX15/2503 Treatment for Huntington's Disease (SIGNAL) \[[@ref001]\].

### Intervention {#sec0025}

VX15/2503 (20 mg/kg), an anti-semaphorin 4D antibody \[[@ref005]\].

### Description {#sec0030}

The SIGNAL trial, sponsored by Vaccinex (Rochester, NY, USA), aims to evaluate the safety, tolerability, pharmacokinetics and efficacy of monthly intra-venous VX15/2503 in adults (≥21 years of age) with late prodromal (i.e. a CAG-age Product superior to 200 and a Unified Huntington's Disease Rating Scale \[UHDRS\] Diagnostic Confidence Level of 2 or 3) and early manifest HD (i.e. a UHDRS Diagnostic Confidence Level of 4 and a UHDRS Total Functional Capacity \[TFC\] above or equal to 11), comparing with intra-venous placebo, for disease modification.

This trial is phase 2, multi-centre, national, randomized, placebo controlled, double-blind, parallel study. It is divided into cohort A and cohort B, and will involve 240 participants. Cohort A recruited 36 participants and was completed in December 2015. In this cohort participants received VX15/2503 or placebo for 6 months, and VX15/2503 for another 6 months in an open label extension, followed by a 3-month period of follow up. Enrolment in cohort B is completed. This cohort is underway and 53 participants will receive VX15/2503 or placebo for 36 months, followed by 3 or 6 months of follow up. The remainder of Cohort B's participants will receive VX15/2503 or placebo for 18 months, followed by 6 months of follow up. The exact numbers and durations have not been confirmed publicly, to our knowledge. The trial has a recruitment target of 240 participants; recruitment is currently open at various sites in the United States of America and Canada.

VX15/2503 is humanized IgG4 monoclonal antibody against semaphorin 4D. Each participant's involvement will last for at least 15 months and up to a maximum of 42 months.

The primary outcome is safety and tolerability. Secondary outcomes involve brain imaging with MRI, FDG-PET, 11C-PBR28 PET; clinical features; pharmacokinetics and pharmacodynamics. Exploratory analysis include cerebrospinal fluid biomarkers.

### Sponsors/funders {#sec0035}

Vaccinex Inc., and the Huntington Study Group.

### Comments {#sec0040}

Semaphorins are a family of proteins whose name derives from semaphore (from the Greek for sign-bearer). Initially described as signalling proteins for neuronal growth and regeneration, today they are known to be involved in many other processes such as the immune response. Semaphorin 4D, or CD100, is an axon-guiding molecule, and a B and T cell modulator.

In a YAC128 transgenic Huntington's disease mouse model, targeting semaphorin 4D with monoclonal antibodies seemed to ameliorate striatal cortical and corpus callosum atrophy, and behavioural phenotype \[[@ref006]\]. However, as of today, there is no published evidence supporting that the semaphorin family may be a therapeutic target in humans with HD.

Previous clinical trials involving 42 patients with advanced solid tumours (4 weekly doses up to 20 mg/kg per week) \[[@ref007]\] and 50 patients with multiple sclerosis (single ascending dose up to 20 mg/kg) \[[@ref008]\] showed VX15/2503 to be relatively well tolerated and safe, but were neither designed nor powered to assess clinical benefit.

Preliminary data from SIGNAL's Cohort A have been presented at public meetings by Vaccinex, reporting interesting neuroimaging and neurometabolic results (PET imaging) in the VX15/2503 arm. Previous reports of atrophy slowing in HD have not ultimately been associated with clinical benefit or slowing of clinical progression \[[@ref009]\], so such reports need to be treated with caution and interpreted in their full context.

COMPLETED CLINICAL TRIALS {#sec0045}
=========================

CREST-E (NCT00712426) {#sec0050}
---------------------

### Study title {#sec0055}

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease \[[@ref002]\].

### Intervention {#sec0060}

Creatine monohydrate, a nutritional supplement.

### Description {#sec0065}

The goal of CREST-E trial was to assess the effects of up to 40 gm of oral creatine monohydrate daily compared with oral placebo on functional decline in adults with early manifest HD (i.e. motor signs characteristic of HD plus a positive family history for HD or a *HTT* CAG repeat length ≥ 36 plus a UHDRS Total Functional Capacity ≥ 7).

This trial was a phase 3, multi-centre, international, randomized, placebo-controlled, double-blind, parallel study. Although designed to recruit 650 participants from Australia, Canada, New Zealand, and the United States, the trial only recruited 553 participants before being halted for futility after an interim analysis. Participant involvement lasted for up to 48 months.

The primary outcome was rate of change from baseline in the UHDRS TFC at weeks 12 to 48 depending on each participant's date of enrolment. The secondary outcomes included changes in other UHDRS scores, adverse events, tolerability, quality of life, and several biofluid and imaging biomarkers.

### Sponsors/funders {#sec0070}

Massachusetts General Hospital, University of Rochester, National Center for Complementary and Integrative Health.

### Results {#sec0075}

The trial was completed on December 2014 and the results published in July 2017 \[[@ref002]\]. CREST-E was the largest clinical trial undertaken in HD. The results showed that although no major safety concerns were noted apart from an increased risk of diarrhoea. Creatine did not have an effect on functional decline in HD, nor on any other outcome studied.

Creatine has previously been studied in pre-symptomatic and symptomatic individuals. In PRECREST (NCT00592995) \[[@ref009]\] 64 premanifest and at-risk individuals were enrolled in a 6-month randomized placebo-controlled double-blinded study of up to 15 gm of oral creatine monohydrate bid, followed by a 12-months open-label extension period. In CREST-HD (NCT00026988) \[[@ref013]\] 69 people with manifest HD were enrolled in a 16-week randomized placebo-controlled double-blinded study of 4 gm of oral creatine monohydrate bid.

As in CREST-E, no safety concerns emerged in PRECREST apart from increased risk of nausea and diarrhoea, but there was no change in clinical measures.

Further creatine clinical trials have been registered and the recruitment is completed (Pre-CREST-X \[NCT01411150\], Pre-CREST-X2 \[NCT01411163\], CREST-X \[NCT01412151\]) but to our knowledge, their results are not public yet.

CONFLICTS OF INTEREST {#sec0080}
=====================

FBR and EJW were sub-investigators on LEGATO-HD (NCT02215616), and are sub-investigators on the IONIS HTT~Rx~ (NCT02519036) and IONIS HTT~Rx~ OLE (NCT03342053) trials, and EJW was a sub-investigator on the Amaryllis study (NCT02197130). The authors did not make use of confidential or privileged information: all materials included in this manuscript were collected from publicly available sources. EJW has participated in scientific advisory boards with Hoffmann-La Roche Ltd, Ionis, Shire, GSK, Wave Life Sciences, PTC Therapeutics and Mitoconix. All honoraria were paid through UCL Consultants Ltd, a wholly owned subsidiary of UCL. Their Host Institution, University College London Hospitals NHS Foundation Trust, has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals.
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